HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Trasidrex (a fixed combination of slow Trasicor 16o mg and Navidrex 0.25mg) in the treatment of hypertension: a multicentre clinical trial in general practice.

Abstract
Sixty-two patients with hypertension who were treated with a free combination of Slow Trasicor or Trasicor and Navidrex K were transferred to a fixed combination tablet, Trasidrex (slow oxprenolol 160 mg + cyclopenthiazide 0.25 mg). Blood pressure control was marginally improved and there was no increase in side-effects.
AuthorsA F Ebbut, R W Elsdon-Dew, J E Murphy
JournalThe Journal of international medical research (J Int Med Res) Vol. 6 Issue 6 Pg. 494-8 ( 1978) ISSN: 0300-0605 [Print] England
PMID720740 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Diuretics
  • Drug Combinations
  • Sodium Chloride Symporter Inhibitors
  • Oxprenolol
  • Cyclopenthiazide
Topics
  • Adult
  • Aged
  • Blood Pressure
  • Cyclopenthiazide (administration & dosage, adverse effects)
  • Diuretics
  • Drug Combinations
  • Female
  • Humans
  • Hypertension (diagnosis, drug therapy)
  • Male
  • Middle Aged
  • Oxprenolol (administration & dosage, adverse effects)
  • Sodium Chloride Symporter Inhibitors (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: